- CEO
- Jie Wu
- Full Time Employees
- 2,645
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Beijing China
- IPO Date
- Aug 2, 2022
- Business
- R&G PharmaStudies Co., Ltd. is a China-based contract research organization that provides full-process, integrated clinical research and development outsourcing services for pharmaceutical, biotechnology, and medical device companies, as well as academic and research institutions globally. Founded in 2008 and headquartered in Beijing, China, the company operates across two principal business segments: Clinical Trial Technical Services and Clinical Trial Related and Laboratory Services. Its comprehensive portfolio of clinical solutions comprises clinical trial operations covering protocol development, project management, medical monitoring, regulatory registration, and pharmacovigilance; site management organization services providing dedicated clinical research coordinators, investigator site selection, patient recruitment, and trial compliance management; clinical data management and biostatistical analysis encompassing electronic data capture implementation, database design, data validation, CDISC-standard dataset conversion, SAS statistical programming, and clinical study report preparation; bioanalytical laboratory services delivering biological sample processing, pharmacokinetic and pharmacodynamic bioassays, biomarker analysis, and immunogenicity testing; clinical pharmacology consulting offering early-phase trial design, quantitative pharmacology modeling, exposure-response analysis, and translational science; and comprehensive regulatory and medical strategy consulting supported by an Innovative Drug Science and Strategy Committee assisting clients with clinical trial applications and marketing authorizations before the National Medical Products Administration, the U.S. Food and Drug Administration, the European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency.
The company maintains extensive operational coverage across mainland China and conducts international operations through its specialized United States subsidiary, R&G US Inc., with offices in Maryland and New Jersey focused on global trial design, regulatory strategy, and advanced biostatistical services. Controlled by ACE UNION HOLDING LIMITED, the company trades on the ChiNext market of the Shenzhen Stock Exchange under the ticker symbol 301333. In recent operational and strategic developments, R&G PharmaStudies expanded its long-standing strategic collaboration with Dassault Systèmes' Medidata, adopting the Medidata Data Experience suite—including Medidata Rave, Randomization and Trial Supply Management, and Data Surveillance solutions—to advance trial digitalization, optimize data quality oversight, and accelerate multi-regional clinical trials. Furthermore, the company instituted an employee equity incentive program to align workforce incentives with long-term growth, refined its internal corporate governance and material reporting frameworks, and broadened its overseas clinical consulting and pharmacology capabilities to support biopharmaceutical developers pursuing international clinical development.